JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

After hours: February 7 at 6:12:20 PM EST Loading Chart for VERA ...

PRAX Praxis Precision Medicines, Inc.

KBC Group NV increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 54.4% in the 4th quarter ...

After hours: 7 February at 18:12:20 GMT-5 ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...